Cargando…

Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer

Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Mitsuru, Takagi, Tadayuki, Suzuki, Rei, Konno, Naoki, Asama, Hiroyuki, Sato, Yuki, Irie, Hiroki, Okubo, Yoshinori, Nakamura, Jun, Takasumi, Mika, Hashimoto, Minami, Kato, Tsunetaka, Kobashi, Ryoichiro, Hikichi, Takuto, Ohira, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Fukushima Society of Medical Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071352/
https://www.ncbi.nlm.nih.gov/pubmed/35197393
http://dx.doi.org/10.5387/fms.2021-32
_version_ 1784700828723970048
author Sugimoto, Mitsuru
Takagi, Tadayuki
Suzuki, Rei
Konno, Naoki
Asama, Hiroyuki
Sato, Yuki
Irie, Hiroki
Okubo, Yoshinori
Nakamura, Jun
Takasumi, Mika
Hashimoto, Minami
Kato, Tsunetaka
Kobashi, Ryoichiro
Hikichi, Takuto
Ohira, Hiromasa
author_facet Sugimoto, Mitsuru
Takagi, Tadayuki
Suzuki, Rei
Konno, Naoki
Asama, Hiroyuki
Sato, Yuki
Irie, Hiroki
Okubo, Yoshinori
Nakamura, Jun
Takasumi, Mika
Hashimoto, Minami
Kato, Tsunetaka
Kobashi, Ryoichiro
Hikichi, Takuto
Ohira, Hiromasa
author_sort Sugimoto, Mitsuru
collection PubMed
description Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future.
format Online
Article
Text
id pubmed-9071352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Fukushima Society of Medical Science
record_format MEDLINE/PubMed
spelling pubmed-90713522022-05-17 Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer Sugimoto, Mitsuru Takagi, Tadayuki Suzuki, Rei Konno, Naoki Asama, Hiroyuki Sato, Yuki Irie, Hiroki Okubo, Yoshinori Nakamura, Jun Takasumi, Mika Hashimoto, Minami Kato, Tsunetaka Kobashi, Ryoichiro Hikichi, Takuto Ohira, Hiromasa Fukushima J Med Sci Review Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future. The Fukushima Society of Medical Science 2022-02-23 2022 /pmc/articles/PMC9071352/ /pubmed/35197393 http://dx.doi.org/10.5387/fms.2021-32 Text en © 2022 The Fukushima Society of Medical Science https://creativecommons.org/licenses/by-nc-sa/4.0/This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. https://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Sugimoto, Mitsuru
Takagi, Tadayuki
Suzuki, Rei
Konno, Naoki
Asama, Hiroyuki
Sato, Yuki
Irie, Hiroki
Okubo, Yoshinori
Nakamura, Jun
Takasumi, Mika
Hashimoto, Minami
Kato, Tsunetaka
Kobashi, Ryoichiro
Hikichi, Takuto
Ohira, Hiromasa
Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title_full Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title_fullStr Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title_full_unstemmed Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title_short Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
title_sort drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071352/
https://www.ncbi.nlm.nih.gov/pubmed/35197393
http://dx.doi.org/10.5387/fms.2021-32
work_keys_str_mv AT sugimotomitsuru drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT takagitadayuki drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT suzukirei drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT konnonaoki drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT asamahiroyuki drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT satoyuki drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT iriehiroki drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT okuboyoshinori drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT nakamurajun drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT takasumimika drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT hashimotominami drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT katotsunetaka drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT kobashiryoichiro drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT hikichitakuto drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer
AT ohirahiromasa drugtreatmentforchemotherapyinducedperipheralneuropathyinpatientswithpancreaticcancer